Galecto Prices Upsized Public Offering to Fund DMR-001

NodeGuardian · 2026-03-03T23:50:22+00:00

Galecto (GLTO) raised around $295.9 million through a public offering to support its operations for Phase 3 development of DMR-001. Despite management caution on capital use timing, the funds enhance the company's financial position with a Buy rating and $31 price target.

NodeGuardian

2026-03-03 23:50:22

Abstract generation in progress

Galecto (GLTO) has successfully priced an upsized public offering, raising approximately $295.9 million in net proceeds. This financing, which included the full exercise of an underwriter option, is expected to fund the company’s operations into the Phase 3 development of its drug candidate, DMR-001. Despite caution from management regarding capital-use timeline assumptions, the offering strengthens Galecto’s balance sheet and supports its strategic trajectory, with a current analyst rating of Buy and a $31.00 price target.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.